Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade

Int J Drug Policy. 2017 Sep:47:107-116. doi: 10.1016/j.drugpo.2017.07.006. Epub 2017 Aug 7.

Abstract

Background: Modelling suggests that achieving the World Health Organization's elimination targets for hepatitis C virus (HCV) is possible by scaling up use of direct-acting antiviral (DAA) therapy. However, poor linkage to health services and retention in care presents a major barrier, in particular among people who inject drugs (PWID). We identify and assess the cost-effectiveness of additional health system interventions required to achieve HCV elimination targets in Australia, a setting where all people living with HCV have access to DAA therapy.

Methods: We used a dynamic HCV transmission and liver-disease progression mathematical model among current and former PWID, capturing testing, treatment and other features of the care cascade. Interventions tested were: availability of point-of-care RNA testing; increased testing of PWID; using biomarkers in place of liver stiffness measurement; and scaling up primary care treatment delivery.

Results: The projected treatment uptake in Australia reduced the number of people living with HCV from approximately 230,000 in 2015 to approximately 24,000 by 2030 and reduced incidence by 45%. However, the majority (74%) of remaining infections were undiagnosed and among PWID. Scaling up primary care treatment delivery and using biomarkers in place of liver stiffness measurement only reduced incidence by a further 1% but saved AU$32 million by 2030, with no change to health outcomes. Additionally replacing HCV antibody testing with point-of-care RNA testing increased healthcare cost savings to AU$62 million, increased incidence reduction to 64% and gained 11,000 quality-adjusted life years, but critically, additional screening of PWID was required to achieve HCV elimination targets.

Conclusion: Even with unlimited and unrestricted access to HCV DAA treatment, interventions to improve the HCV cascade of care and target PWID will be required to achieve elimination targets.

Keywords: Cascade of care; Community-based services; Cost-effectiveness; Elimination; Hepatitis C virus; Mathematical model; People who inject drugs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / therapeutic use
  • Australia / epidemiology
  • Cost-Benefit Analysis
  • Health Care Costs
  • Hepatitis C / complications
  • Hepatitis C / diagnosis
  • Hepatitis C / drug therapy*
  • Hepatitis C / epidemiology*
  • Humans
  • Models, Theoretical
  • Patient Acceptance of Health Care*
  • Point-of-Care Systems
  • Primary Health Care / statistics & numerical data*
  • Substance Abuse, Intravenous / complications
  • Substance Abuse, Intravenous / psychology

Substances

  • Antiviral Agents